Glesatinib
- Generic Name
- Glesatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C31H27F2N5O3S2
- CAS Number
- 936694-12-1
- Unique Ingredient Identifier
- 7Q29OXD98N
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT02954991
- Locations
- ๐บ๐ธ
Yuma Regional Medical Center, Yuma, Arizona, United States
๐บ๐ธUSOR - Texas Oncology - Denison Cancer Center, Denison, Texas, United States
๐บ๐ธMinnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT02544633
- Locations
- ๐บ๐ธ
Georgetown University Medical Center, Washington, District of Columbia, United States
๐บ๐ธUniversity of California San Diego, La Jolla, California, United States
๐บ๐ธEastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01930006
- Locations
- ๐บ๐ธ
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States
Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT00697632
- Locations
- ๐ฐ๐ท
National Cancer Center, Gyeonggi-do, Korea, Republic of
๐จ๐ฆCross Cancer Institute, Edmonton, Alberta, Canada
๐จ๐ฆBritish Columbia Cancer Agency, Vancouver Center, Vancouver, British Columbia, Canada
Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT00679133
- Locations
- ๐บ๐ธ
Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธUniversity of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.